Back

GLP-1 receptor agonists for anthracycline-associated cardiac outcomes: first meta-analytic evaluation in propensity-matched cohorts

30 August 2026 (14:54 - 15:06)
Organised by: Logo
Congress Presentation Part of: Predicting and preventing cancer therapy–related cardiac dysfunction: from artificial intelligence to cardiometabolic protection Cardio-Oncology ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Anchit Chauhan

(India)

3 More presentations in this session

Presentation thumbnail
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased risk of diastolic dysfunction in a cardio-oncology cohort
Mr J. Singh (US)
Abstract Slides Video
Presentation thumbnail
Artificial intelligence–enabled electrocardiography as a pre-treatment predictor of chemotherapy-related cardiac dysfunction
Doctor M. Lee (Bucheon, KR)
Abstract Slides Video
Presentation thumbnail
Stratification of cancer-therapy related cardiac dysfunction: a validated prediction tool to identify low risk patients.
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides

Access the full session

Session thumbnail
Predicting and preventing cancer therapy–related cardiac dysfunction: from artificial intelligence to cardiometabolic protection
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 14:54 CET
You may be interested in
thumbnail
Congress Presentation
Role of GLP-1 in cardio-oncology
21 June 2025
thumbnail
Congress Presentation
GLP-1 receptor agonists reduce infarct size relative to area at risk in myocardial infarction: a meta-analysis of randomized controlled trials
30 August 2026
thumbnail
Congress Presentation
Cardiovascular outcomes of sodium glucose co-transporter-2 inhibitor treatment in cancer patients receiving anthracycline chemotherapy: a systematic review and meta-analysis
30 August 2025
thumbnail
Congress Presentation
Sacubitril/valsartan in anthracycline-treated patients: a systematic review and meta-analysis of available evidence.
19 June 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources